• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Synthetic Beta-Lactam Antibiotics as a Selective Breast Cancer Cell Apoptosis Inducer: Significance in Breast Cancer Prevention and Treatment.
【24h】

Synthetic Beta-Lactam Antibiotics as a Selective Breast Cancer Cell Apoptosis Inducer: Significance in Breast Cancer Prevention and Treatment.

机译：合成的β-内酰胺抗生素作为选择性乳腺癌细胞凋亡诱导剂：在乳腺癌预防和治疗中的意义。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Activation of the cellular apoptotic program is a current strategy for the prevention and treatment of human cancer including breast cancer. Because of the ease of synthesis and structural manipulation, small molecules with apoptosis-inducing ability have great potential to be developed into chemotherapeutic drugs. The b-lactam antibiotics have for the past 60 years played an essential role in treating bacterial infections without causing toxic side effects in the host. We hypothesized that active N-thiolated b-lactams can target a tumor-specific protein(s) and selectively induce apoptosis in human breast cancer but not normal cells. In this report, we have designed and synthesized a number of beta-lactams with selected C3 and C4 ring substituents, and evaluated their potencies to inhibit proliferation and induce apoptosis in human breast cancer, but not normal cells. We have also studied the biochemical targets of these b-lactams by synthesizing and using labeled compounds as well as by performing microarray assay. Our results supported by this IDEA award and the Concept Award strongly support our hypothesis that beta-lactams cause tumor DNA damage, which is responsible for their anti-tumor activities. Our studies have provided strong support for proof-of-concept of the potential use of these b-lactams in breast cancer prevention and treatment.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号